Proprotein Convertase Subtilisin/Kexin Type 9 and Inflammation: An Updated Review [PDF]
Frontiers in Cardiovascular Medicine, 2022 The function of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), a novel plasma protein, has mainly been involved in cholesterol metabolism in the liver, while, more interestingly, recent data have shown that PCSK9 also took part in the modulation ...
Na-qiong Wu, Jian-jun Li
exaly +6 more sources
Perkembangan Implikasi Biologi dan Klinis Proprotein Convertase Subtilisin-Kexin 9 [PDF]
Majalah Kardiologi Indonesia, 2017 Pada tahun 2003 Proprotein Convertase Subtilisin-Kexin 9 (PCSK9) berhasil diidentifikasi.1 PCSK9 berfungsi meningkatkan kadar LDL Cholesterol (LDL-C) melalui degradasi LDL Receptor (LDLR).2 Penemuan PCSK9 telah merevolusi serta merupakan perkembangan ...
Sargowo, Djanggan
doaj +3 more sources
Proprotein Convertase Subtilisin/Kexin 9 as a Modifier of Lipid Metabolism in Atherosclerosis
Biomedicines, 2023 Despite being the most common treatment strategy in the management of atherosclerosis and subsequent cardiovascular disease, classical statin therapy has certain disadvantages, including numerous side effects.
Anastasia V. Poznyak +5 more
doaj +3 more sources
The unique role of proprotein convertase subtilisin/kexin 9 in cholesterol homeostasis [PDF]
Journal of Internal Medicine, 2009 Abstract.The LDL receptor (LDLR) plays an essential role in the regulation of plasma (LDL) cholesterol concentrations by virtue of its ability to clear plasma LDL. Down‐regulation of the LDLR by proprotein convertase subtilisin/kexin 9 (PCSK9) has recently emerged as a regulatory mechanism that controls plasma LDL cholesterol concentrations. Studies in
Seyed Ali Mousavi +2 more
openalex +4 more sources
Immunization against proprotein convertase subtilisin-like/kexin type 9 lowers plasma LDL-cholesterol levels in mice [PDF]
Journal of Lipid Research, 2012 Successful development of drugs against novel targets crucially depends on reliable identification of the activity of the target gene product in vivo and a clear demonstration of its specific functional role for disease development.
Elena Fattori +10 more
doaj +2 more sources
Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9 [PDF]
Oncotarget, 2017 The protein complex proprotein convertase subtilisin/kexin type 9 (PCSK9) serves as an important target for the prevention and treatment of atherosclerosis and lipid homeostasis. This study investigated the effect of cilostazol on plasma PCSK9 concentrations.
I‐Chih Chen +5 more
openalex +4 more sources
Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor [PDF]
JACC: Case Reports, 2020 A 72-year-old man with coronary artery disease, statin intolerance, and chronic kidney disease stage IIIa was initiated on alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, and developed acute kidney injury.
June K. Pickett, MD +6 more
doaj +3 more sources
The role of proprotein convertase subtilisin/kexin type 9 inhibitors in managing cardiovascular risk [PDF]
South African Family Practice, 2016 Hypercholesterolaemia and dyslipidaemia, marked by decreased levels of high-density lipoprotein and elevated levels of lowdensity lipoprotein (LDL), increase the risk of cardiovascular disease.
Natalie Schellack +2 more
doaj +3 more sources
Frontiers in Aging Neuroscience, 2019 Alzheimer’s disease (AD) has been associated with dysregulation of brain cholesterol homeostasis. Proprotein convertase subtilisin/kexin type 9 (PCSK9), beyond the known role in the regulation of plasma low-density lipoprotein cholesterol, was first ...
Massimiliano Ruscica +2 more
exaly +3 more sources
ASSOCIATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 WITH HYPERTENSION AND SMOKING
Инновационная медицина Кубани, 2019 Objectives. To estimate the relationship of proprotein convertase subtilisin/kexin type 9 (PCSK9) level with blood pressure (BP) and smoking in a population of young males in Novosibirsk.Material and methods.
K. S. Benimetskaya +6 more
doaj +3 more sources